Wave Life Sciences stock trades at EUR 3.02 after Research Day

Published on 11/08/2026 at 14:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wave Life Sciences stock remains tied to an RNA medicines pipeline spanning rare and prevalent disorders. Its lead programs target three disease areas.

Key points for investors

Wave Life Sciences held its 2026 Virtual Research Day on November 4.
Its lead programs target obesity, alpha-1 antitrypsin deficiency and PNPLA3 I148M liver disease.

WVE, US94352A1043, Illustration mit AI erstellt.

Wave Life Sciences held its 2026 Virtual Research Day on Wednesday, November 4, according to the Wave Life Sciences investor relations site. The event followed the company's third-quarter 2026 earnings call on October 27.

Wave Life Sciences stock traded at 3.02 euros on Lang & Schwarz at 1:04 p.m. CET on Saturday, November 7, 2026.

RNA medicines drive pipeline strategy

Wave describes itself as a biotechnology company focused on RNA medicines. Its PRISM platform combines RNA editing, splicing, RNA interference and antisense silencing to develop candidates for rare and prevalent disorders.

The company's lead programs include WVE-007 for obesity, WVE-006 for alpha-1 antitrypsin deficiency and WVE-008 for PNPLA3 I148M liver disease. Wave also lists several preclinical programs that use its broader RNA medicines platform.

Investors can follow the real-time quote of Wave Life Sciences stock on the company page.

The S&P 500 provides the broader US equity-market backdrop: S&P 500 market coverage.

More updates are available in more news and analyses on Wave Life Sciences stock.